Posted 24 October 2012 - 09:06 PM
It seems premature to combine bosutinib with anything since it has not proven itself against CML. And especially combining bosutinib with danusertib (a pan-aurora kinase inhibitor) is a bit odd. The Aurora kinase inhibitors have a questionable history, and some have been abandoned after severe impact on the heart. I personally think the pan-aurora kinase inhibitors should only be used where there is no other option. For the gatekeeper mutation (T315i) there is Ponatinib, which should be used first.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users